


RealRate

PHARMACEUTICAL 2021

GT Biopharma Inc. Rank 35 of 409







RealRate

PHARMACEUTICAL 2021

## GT Biopharma Inc. Rank 35 of 409

The relative strengths and weaknesses of GT Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GT Biopharma Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 592% points. The greatest weakness of GT Biopharma Inc. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 670% points.

The company's Economic Capital Ratio, given in the ranking table, is 135%, being 490% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	5,661
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	35,094
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	21,532
Property and Equipment	0
Research and Development	485
Revenues	0
Selling, General and Administrative Expense	6,279

Output Variable	Value in 1000 USD
Assets	5,661
Liabilities	35,094
Expenses	6,764
Stockholders Equity	-29,433
Net Income	14,768
Comprehensive Net Income	14,768
Economic Capital Ratio	135%

